dopamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 947 51-61-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dopamine
  • oxytyramine
  • dopamin
  • dophamine
  • hydroxytyramin
  • dopamine hydrochloride
  • dopamine HCl
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
  • Molecular weight: 153.18
  • Formula: C8H11NO2
  • CLOGP: 0.17
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 3
  • TPSA: 66.48
  • ALOGS: -1.31
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 470 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.74 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 65.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 25, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 92.68 25.26 52 3429 50285 50551358
Cardiac arrest 64.14 25.26 50 3431 83601 50518042
Renal ischaemia 62.24 25.26 13 3468 569 50601074
PCO2 increased 53.51 25.26 13 3468 1130 50600513
PO2 increased 52.37 25.26 12 3469 810 50600833
Blood bicarbonate decreased 50.95 25.26 15 3466 2710 50598933
Hypotension 50.56 25.26 71 3410 235398 50366245
Cardiogenic shock 48.64 25.26 23 3458 15576 50586067
Diabetes insipidus 48.57 25.26 14 3467 2350 50599293
Oxygen saturation abnormal 46.72 25.26 14 3467 2688 50598955
Blood pH decreased 43.66 25.26 13 3468 2442 50599201
Status epilepticus 42.51 25.26 20 3461 13386 50588257
Ventricular tachycardia 42.30 25.26 21 3460 15800 50585843
Foetal death 41.54 25.26 17 3464 8163 50593480
Enzyme induction 37.50 25.26 6 3475 56 50601587
Renal impairment 37.04 25.26 35 3446 75626 50526017
Shock 34.37 25.26 20 3461 20630 50581013
Renal injury 34.10 25.26 15 3466 8596 50593047
Pulmonary oedema 32.66 25.26 27 3454 48911 50552732
Newborn persistent pulmonary hypertension 32.21 25.26 6 3475 144 50601499
Bradycardia 31.90 25.26 30 3451 64396 50537247
Cardiopulmonary failure 31.70 25.26 11 3470 3362 50598281
Cardiac assistance device user 31.42 25.26 5 3476 45 50601598
Electroencephalogram abnormal 31.30 25.26 11 3470 3488 50598155
Seizure 30.50 25.26 39 3442 117835 50483808
Blood magnesium decreased 30.38 25.26 15 3466 11145 50590498
Renal failure 30.34 25.26 37 3444 106596 50495047
Disseminated intravascular coagulation 29.59 25.26 17 3464 17118 50584525
Clonus 29.40 25.26 11 3470 4164 50597479
Metabolic acidosis 29.25 25.26 23 3458 38802 50562841
Drug ineffective 28.42 25.26 121 3360 819212 49782431
Left ventricular dysfunction 28.24 25.26 14 3467 10492 50591151
Blood pressure decreased 27.61 25.26 26 3455 55883 50545760
Electrocardiogram QRS complex prolonged 26.77 25.26 11 3470 5333 50596310
Systolic anterior motion of mitral valve 26.42 25.26 4 3477 25 50601618

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 54.39 20.11 52 3630 63064 29507781
Drug ineffective 48.21 20.11 125 3557 363045 29207800
Disseminated intravascular coagulation 47.29 20.11 30 3652 19950 29550895
Ventricular fibrillation 40.55 20.11 25 3657 15808 29555037
Hypotension 39.08 20.11 79 3603 194275 29376570
Torsade de pointes 38.27 20.11 18 3664 6643 29564202
Blood urea increased 38.05 20.11 30 3652 28082 29542763
Shock 29.30 20.11 23 3659 21381 29549464
Metabolic acidosis 28.61 20.11 29 3653 37633 29533212
Acute kidney injury 27.80 20.11 84 3598 265183 29305662
Cardiogenic shock 27.08 20.11 21 3661 19169 29551676
Cardiac arrest 25.03 20.11 41 3641 85550 29485295
Neutrophil count increased 24.97 20.11 18 3664 14724 29556121
Lymphocyte count decreased 24.85 20.11 20 3662 19251 29551594
Acidosis 24.02 20.11 15 3667 9690 29561155
Dry gangrene 22.94 20.11 6 3676 385 29570460
Respiratory failure 22.51 20.11 42 3640 97089 29473756
Hypernatraemia 22.37 20.11 13 3669 7373 29563472
Renal failure 22.33 20.11 47 3635 118552 29452293
Incision site pain 20.91 20.11 8 3674 1775 29569070

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 101.13 21.64 83 6447 101330 64390872
Hypotension 74.69 21.64 136 6394 380838 64111364
Cardiac arrest 73.39 21.64 84 6446 153980 64338222
Disseminated intravascular coagulation 71.12 21.64 43 6487 32305 64459897
Cardiogenic shock 65.91 21.64 41 6489 32386 64459816
Blood urea increased 58.93 21.64 43 6487 44110 64448092
Ventricular fibrillation 58.40 21.64 34 6496 23826 64468376
Drug ineffective 57.95 21.64 201 6329 840046 63652156
Shock 55.05 21.64 39 6491 38201 64454001
Ventricular tachycardia 49.45 21.64 35 6495 34230 64457972
Renal ischaemia 49.20 21.64 13 6517 1070 64491132
PCO2 increased 48.04 21.64 14 6516 1653 64490549
Metabolic acidosis 44.86 21.64 45 6485 70913 64421289
Diabetes insipidus 41.34 21.64 16 6514 4505 64487697
Respiratory failure 41.34 21.64 65 6465 161118 64331084
Septic shock 41.14 21.64 52 6478 105385 64386817
PO2 increased 40.66 21.64 12 6518 1480 64490722
Foetal death 40.46 21.64 17 6513 5913 64486289
Blood pH decreased 38.21 21.64 15 6515 4387 64487815
Oxygen saturation abnormal 37.57 21.64 14 6516 3557 64488645
Blood bicarbonate decreased 36.86 21.64 15 6515 4814 64487388
Acute kidney injury 36.60 21.64 114 6416 449126 64043076
Renal impairment 33.98 21.64 54 6476 134963 64357239
Renal failure 33.11 21.64 63 6467 181625 64310577
Torsade de pointes 32.88 21.64 21 6509 17342 64474860
Bradycardia 32.14 21.64 49 6481 118170 64374032
Platelet count decreased 31.60 21.64 59 6471 167652 64324550
Enzyme induction 31.48 21.64 6 6524 109 64492093
Blood pressure decreased 31.24 21.64 41 6489 86158 64406044
Pulmonary oedema 30.99 21.64 39 6491 78635 64413567
Neutrophil count increased 30.18 21.64 23 6507 25151 64467051
Acidosis 29.97 21.64 20 6510 17775 64474427
Fatigue 29.40 21.64 20 6510 748710 63743492
Hypernatraemia 28.84 21.64 17 6513 12172 64480030
Status epilepticus 28.66 21.64 21 6509 21642 64470560
Cardiac assistance device user 28.02 21.64 5 6525 62 64492140
Sepsis 27.18 21.64 67 6463 230274 64261928
Arthralgia 26.83 21.64 6 6524 442254 64049948
Incision site pain 26.44 21.64 10 6520 2644 64489558
Left ventricular dysfunction 26.04 21.64 18 6512 16936 64475266
Seizure 25.74 21.64 54 6476 166838 64325364
Systolic dysfunction 24.62 21.64 10 6520 3192 64489010
Blood magnesium decreased 24.31 21.64 16 6514 13889 64478313
Cardiac failure 22.99 21.64 45 6485 132328 64359874
Electroencephalogram abnormal 22.96 21.64 11 6519 5192 64487010
Hepatic function abnormal 22.38 21.64 30 6500 64283 64427919
N-terminal prohormone brain natriuretic peptide 22.17 21.64 4 6526 53 64492149
Systolic anterior motion of mitral valve 22.17 21.64 4 6526 53 64492149
Urine output decreased 21.85 21.64 16 6514 16476 64475726

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA04 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA CS M0003647 Catecholamines
FDA EPC N0000175570 Catecholamine
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Low cardiac output syndrome indication 44088000
Low blood pressure indication 45007003
Decompensated cardiac failure indication 195111005
Sinus bradycardia off-label use 49710005
Acute nephropathy off-label use 58574008
Tachyarrhythmia contraindication 6285003
Hypovolemia contraindication 28560003
Ventricular arrhythmia contraindication 44103008
Acidosis contraindication 51387008
Pheochromocytoma contraindication 302835009
Hypoxia contraindication 389086002
Occlusive Vascular Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.96 acidic
pKa2 12.98 acidic
pKa3 10.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST Ki 5 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Kd 4.19 CHEMBL
D(1A) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(2) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter IC50 8.18 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5.08 PDSP
D(3) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
D(1B) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.19 CHEMBL
D(4) dopamine receptor GPCR AGONIST Ki 9 WOMBAT-PK
Trace amine-associated receptor 1 GPCR Ki 6.38 WOMBAT-PK
Melatonin receptor type 1A GPCR Ki 5.15 CHEMBL
Melatonin receptor type 1B GPCR Ki 5.04 CHEMBL
Lysine-specific demethylase 4E Enzyme IC50 5.52 CHEMBL
Dopamine beta-hydroxylase Enzyme Km 3 WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.85 CHEMBL
Alpha-synuclein Transporter IC50 6.28 CHEMBL
D(2) dopamine receptor GPCR Ki 8.35 CHEMBL
Sodium-dependent dopamine transporter Transporter IC50 6.70 CHEMBL
D(1A) dopamine receptor GPCR Ki 8.15 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.82 CHEMBL
D(2) dopamine receptor GPCR Ki 8.74 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 4.30 CHEMBL
D(3) dopamine receptor GPCR Ki 7.96 CHEMBL
D(4) dopamine receptor GPCR EC50 8.62 CHEMBL
Opioid receptor GPCR IC50 5.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.24 CHEMBL
Dopamine receptor GPCR IC50 8.43 CHEMBL
Dopamine receptor GPCR IC50 5.27 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 4.85 CHEMBL
Adenylate cyclase Enzyme EC50 5.46 CHEMBL
Adenosine A2b receptor GPCR Ki 6.01 CHEMBL
M18 aspartyl aminopeptidase Enzyme IC50 5.70 CHEMBL

External reference:

IDSource
4019733 VUID
N0000147825 NUI
D00633 KEGG_DRUG
62-31-7 SECONDARY_CAS_RN
4018656 VANDF
4019733 VANDF
C0013030 UMLSCUI
CHEBI:18243 CHEBI
LDP PDB_CHEM_ID
CHEMBL59 ChEMBL_ID
DB00988 DRUGBANK_ID
CHEMBL1557 ChEMBL_ID
D004298 MESH_DESCRIPTOR_UI
681 PUBCHEM_CID
2417 INN_ID
940 IUPHAR_LIGAND_ID
VTD58H1Z2X UNII
3628 RXNORM
3090 MMSL
4632 MMSL
6641 MMSL
d00216 MMSL
001787 NDDF
004721 NDDF
16257000 SNOMEDCT_US
412383006 SNOMEDCT_US
59187003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9252 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9252 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9253 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9253 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9254 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9254 INJECTION 40 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9255 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9255 INJECTION 80 mg INTRAVENOUS ANDA 16 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1840 INJECTION 80 mg INTRAVENOUS EXPORT ONLY 20 sections
MYOCARD-DX HUMAN PRESCRIPTION DRUG LABEL 2 0264-1880 INJECTION 800 mg INTRAVENOUS EXPORT ONLY 20 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1005 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1007 INJECTION, SOLUTION 160 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1009 INJECTION, SOLUTION 320 mg INTRAVENOUS NDA 22 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9981 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9982 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-5820 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7809 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 25 sections
Dopamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-7810 INJECTION, SOLUTION 3.20 mg INTRAVENOUS NDA 25 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-9104 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1220 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1291 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 12 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1316 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 13 sections
DOPAMINE HCI IN 5% DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1458 INJECTION, SOLUTION 1.60 mg INTRAVENOUS NDA 13 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1489 INJECTION 40 mg INTRAVENOUS ANDA 11 sections
DOPAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1490 INJECTION 40 mg INTRAVENOUS ANDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 52584-104 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
Dopamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 52584-820 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 11 sections
DOPamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7066 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS NDA 17 sections